Controls rapid ventricular rate in atrial fibrillation or atrial flutter. ANDA 216552, held by Eugia Pharma. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 216552 (Diltiazem Hydrochloride), held by Eugia Pharma, was first approved by FDA on Mar 29, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diltiazem Hydrochloride5MG/ML · injectable;injection | Diltiazem Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters